BioMed Central
Page 1 of 13
(page number not for citation purposes)
BMC Biology
Research article Open Access
The calcium-sensing receptor regulates parathyroid hormone gene 
expression in transfected HEK293 cells
Hillel Galitzer, Vardit Lavi-Moshayoff, Morris Nechama, Tomer Meir, 
Justin Silver and Tally Naveh-Many*
Address: Minerva Center for Calcium and Bone Metabolism, Nephrology Services, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Email: Hillel Galitzer - hillelgalitzer@gmail.com; Vardit Lavi-Moshayoff - vardit.lavi-moshayoff@mail.huji.ac.il; 
Morris Nechama - mnehama@gmail.com; Tomer Meir - tomer.meir@mail.huji.ac.il; Justin Silver - silver@huji.ac.il; Tally Navehï¿¾Many* - tally@cc.huji.ac.il
* Corresponding author 
Abstract
Background: The parathyroid calcium receptor determines parathyroid hormone secretion and
the response of parathyroid hormone gene expression to serum Ca2+ in the parathyroid gland.
Serum Ca2+ regulates parathyroid hormone gene expression in vivo post-transcriptionally affecting
parathyroid hormone mRNA stability through the interaction of trans-acting proteins to a defined
cis element in the parathyroid hormone mRNA 3'-untranslated region. These parathyroid hormone
mRNA binding proteins include AUF1 which stabilizes and KSRP which destabilizes the parathyroid
hormone mRNA. There is no parathyroid cell line; therefore, we developed a parathyroid
engineered cell using expression vectors for the full-length human parathyroid hormone gene and
the human calcium receptor.
Results: Co-transfection of the human calcium receptor and the human parathyroid hormone
plasmid into HEK293 cells decreased parathyroid hormone mRNA levels and secreted parathyroid
hormone compared with cells that do not express the calcium receptor. The decreased
parathyroid hormone mRNA correlated with decreased parathyroid hormone mRNA stability in
vitro, which was dependent upon the 3'-UTR cis element. Moreover, parathyroid hormone gene
expression was regulated by Ca2+ and the calcimimetic R568, in cells co-transfected with the
calcium receptor but not in cells without the calcium receptor. RNA immunoprecipitation analysis
in calcium receptor-transfected cells showed increased KSRP-parathyroid hormone mRNA binding
and decreased binding to AUF1. The calcium receptor led to post-translational modifications in
AUF1 as occurs in the parathyroid in vivo after activation of the calcium receptor.
Conclusion: The expression of the calcium receptor is sufficient to confer the regulation of
parathyroid hormone gene expression to these heterologous cells. The calcium receptor decreases
parathyroid hormone gene expression in these engineered cells through the parathyroid hormone
mRNA 3'-UTR cis element and the balanced interactions of the trans-acting factors KSRP and AUF1
with parathyroid hormone mRNA, as in vivo in the parathyroid. This is the first demonstration that
the calcium receptor can regulate parathyroid hormone gene expression in heterologous cells.
Published: 27 April 2009
BMC Biology 2009, 7:17 doi:10.1186/1741-7007-7-17
Received: 3 October 2008
Accepted: 27 April 2009
This article is available from: http://www.biomedcentral.com/1741-7007/7/17
Â© 2009 Galitzer et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 2 of 13
(page number not for citation purposes)
Background
Parathyroid hormone (PTH) regulates calcium homeostaï¿¾sis and bone metabolism. Changes in extracellular Ca2+
([Ca2+]o) are sensed by the parathyroid G-protein coupled
calcium receptor (CaR) [1]. The CaR determines the
response of the parathyroid to [Ca2+]o at the levels of PTH
secretion, PTH gene expression and parathyroid cell proï¿¾liferation [2,3]. Increased [Ca2+]o activates the CaR, resultï¿¾ing in a G-protein-dependent activation of PLC, PLA2 and
PLD [4]. This results in decreased PTH secretion and parï¿¾athyroid cell proliferation. Calcimimetics bind transmemï¿¾brane (TM) 6 and TM7 of the CaR to allosterically alter the
conformation of the CaR [5,6]. The calcimimetic R568
decreases PTH secretion, PTH mRNA levels and parathyï¿¾roid cell proliferation [7,8]. Genetic deletion of Gq/11 speï¿¾cifically in the parathyroid leads to severe
hyperparathyroidism (HPT) [9]. Similarly, CaR-/- mice are
not viable due to the severe HPT [10] and can be rescued
by mating with PTH-/- or GCM2-/- mice, where PTH is
either absent or markedly reduced [11,12]. Therefore, the
CaR and its signal transduction are central to parathyroid
physiology and the maintenance of a normal serum PTH
and intact Ca2+ homeostasis.
Low serum Ca2+ and chronic kidney disease lead to secï¿¾ondary hyperparathyroidism which is characterized by
increased PTH mRNA levels in experimental models [13].
The increased PTH mRNA in vivo is post-transcriptional
and is mediated by the interaction of trans-acting proteins
to a defined cis-acting AU-rich element (ARE) in the PTH
mRNA 3'-untranslated region (UTR) [14-16]. A 26-nucleï¿¾otide sequence within the ARE is conserved among species
and is both necessary and sufficient for protein binding
and the regulation of PTH mRNA stability by dietary calï¿¾cium or phosphorus depletion [16,17]. AU-rich binding
factor 1 (AUF1) and Upstream of N-ras (Unr) are PTH
mRNA trans-acting proteins that stabilize PTH mRNA
[18,19]. The binding of these proteins to the PTH mRNA
3'-UTR is regulated in the parathyroid by chronic hypocï¿¾alcemia, hypophosphatemia and experimental kidney
failure as well as by the calcimimetic R568 [7,15,16]. We
have recently identified the decay-promoting protein
KSRP (KH domain splicing regulatory protein) as an addiï¿¾tional PTH mRNA 3'-UTR binding protein that deterï¿¾mines PTH mRNA stability in transfected cells [20]. KSRPï¿¾PTH mRNA interaction is increased in parathyroids from
hypophosphatemic rats, where PTH mRNA is unstable,
and decreased in parathyroids from hypocalcemic and
experimental renal failure rats, where the PTH mRNA is
more stable. The balanced interaction of PTH mRNA with
AUF1 and KSRP determines PTH mRNA half-life and levï¿¾els and hence serum PTH levels [20].
There is no parathyroid cell line and the signal transducï¿¾tion pathway whereby [Ca2+]o regulates PTH secretion has
been characterized by using bovine parathyroid cells in
suspension and rat parathyroid organ cultures [21,22].
Parathyroid hormone gene expression and its regulation
in cells in vitro have been studied in primary cultures of
bovine parathyroids [23,24]. HEK293 cells transfected
with the CaR faithfully maintain an intact signal transducï¿¾tion after the stimulus of a high [Ca2+]o to activate the
mitogen-activated protein kinase (MAPK) pathway
[25,26]. We have now utilized this transfected heteroloï¿¾gous cell system to study the mechanisms whereby the
CaR regulates PTH gene expression. As the regulation of
PTH gene expression by [Ca2+]o is predominantly postï¿¾transcriptional, we studied PTH mRNA stability in a sysï¿¾tem that was independent of any effect on PTH transcripï¿¾tion through the PTH promoter. To do this we expressed
PTH mRNA driven by a viral promoter to express large
amounts of PTH mRNA in HEK293 cells. Differences in
PTH mRNA levels would therefore represent only postï¿¾transcriptional regulation. Expression of the CaR markï¿¾edly decreased PTH mRNA levels and stability and conï¿¾ferred responsiveness to [Ca2+]o and the calcimimetic
R568 in these cells. This was mediated by the PTH mRNA
3'-UTR ARE. Moreover, expression of the CaR in the
HEK293 cells led to a shift from the interaction of the PTH
mRNA with the stabilizing protein, AUF1, to the destabiï¿¾lizing protein, KSRP. Furthermore, the expression of CaR
modified AUF1 post-translationally as previously shown
in vivo [7,27]. Therefore, the expression of the CaR in this
heterologous cell system reproduces the signal transducï¿¾tion that determines PTH gene expression in the parathyï¿¾roid.
Results
The calcium receptor decreases parathyroid hormone 
mRNA levels post-transcriptionally in HEK293 cells
PTH gene expression is regulated post-transcriptionally by
Ca2+ and calcimimetics affecting PTH mRNA stability
[7,15]. To focus on the effect of the CaR on PTH mRNA
stability in a cell system we constructed an expression vecï¿¾tor containing the full-length human PTH gene including
its three exons and two introns (hPTH) driven by a viral
SV40 (not shown) or CMV promoter (Figure 1A). Expresï¿¾sion of PTH from both viral promoters gave similar results
and we used the CMV promoter for further studies.
The hPTH expression plasmid was transiently transfected
into HEK293 cells. The transcribed PTH mRNA was corï¿¾rectly spliced resulting in PTH mRNA of the expected size
(Figure 1D). The PTH mRNA was translated into mature
human PTH that was measured in the medium by radioï¿¾immunoassay (Figure 1F). We then studied the effect of
the CaR on PTH mRNA levels in HEK293 cells expressing
the PTH gene by transient transfection. The expression of
the CaR was confirmed by immunohistochemistry on
whole cells using an intact cell enzyme-linked immu-

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 3 of 13
(page number not for citation purposes)
Figure 1 (see legend on next page)
B
antibody CaR -
CaR -
CaR +
background
G
PTH/HPRT mRNA
(fold change)
0
0.5
1.0
1.5
CaR - CaR + PTH1R
*
F
0
0.2
0.4
0.6
0.8
1
1.2
secreted PTH
(fold change)
CaR - CaR + 
*
PTH
GFP
CaR - +
28S
18S
hPTH/GFP 1Â±0.18 0.26Â±0.03* 
D E
PTH/GH mRNA 
(fold change)
0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
CaR - CaR +
*
C
CaR - +
CaR
myc
kDa
250
150
100
50
A
3â€™UTR
Pre Pro PTH
5â€™UTR
intron A intron B
CMV

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 4 of 13
(page number not for citation purposes)
noassay to determine cell surface expression [28] (Figure
1B) and by western blot (Figure 1C). Transfection effiï¿¾ciency was >95%, as indicated by fluorescent microscopy
of the cells co-transfected with a green fluorescent protein
(GFP) expression plasmid (not shown). Co-transfection
of the human (h) CaR together with the hPTH plasmid
resulted in a marked decrease in PTH mRNA levels by
Northern blot (Figure 1D) and real time RT PCR (qPCR)
(Figure 1E) corrected for co-transfected control genes GH
(Figure 1E) or endogenous HPRT (Figure 1G). The
decrease in PTH mRNA by the CaR was reflected in a
decrease in secreted PTH at 48 h (Figure 1F). Transfection
with another G protein coupled receptor (GPCR), the PTH
receptor (PTH1R) had no effect on PTH mRNA levels,
confirming the specificity of the CaR effect on PTH mRNA
(Figure 1G).
The calcium receptor decreases parathyroid hormone 
mRNA levels through the parathyroid hormone mRNA 3'-
UTR AU-rich element
We have previously reported that the regulation of PTH
mRNA levels is dependent upon a cis-acting instability
ARE in the PTH mRNA 3'-UTR [15,16,20]. We then deterï¿¾mined if the regulation of PTH mRNA levels by the CaR is
exerted through the PTH mRNA ARE, using a growth horï¿¾mone (GH) reporter gene containing either the rat PTH 63
nt ARE (GH63) or a truncated non-functional PTH mRNA
40 nt element [29]. Over-expression of the CaR decreased
GH63 mRNA levels but had no effect on wild-type GH
mRNA levels or on a GH mRNA with the truncated 40 nt
PTH mRNA ARE (Figure 2A). Our results indicate that the
CaR specifically decreases PTH mRNA levels through the
PTH mRNA ARE.
To study the effect of the CaR on PTH mRNA stability we
used an in vitro degradation assay (IVDA) [16,20]. A radiï¿¾olabeled polyadenylated in vitro-transcribed hPTH mRNA
was incubated with extracts from cells transfected with
either the CaR expression plasmid or a control plasmid.
The amount of intact PTH mRNA remaining with time
represents the decay of the transcript by the different
extracts and is indicative of the decay rate in vivo [15,30].
The rate of PTH mRNA decay was increased by extracts
from cells expressing the CaR compared with extracts
from cells with control plasmid correlating with PTH
mRNA levels in the transfected cells (Figure 2B, top gel
and Figure 2C). We then performed IVDA using polyadeï¿¾nylated PTH mRNA with an internal deletion of the ARE
(Figure 2B, bottom gel and Figure 2C). The PTH mRNA
transcript lacking the ARE was stable throughout the
experiment and in contrast to the full-length PTH mRNA,
was not affected by expression of the CaR (Figure 2B and
2C). Our results indicate that the CaR specifically
decreases steady-state PTH mRNA levels and PTH mRNA
stability through the PTH mRNA ARE.
Protein-PTH mRNA interactions by RNA 
immunoprecipitation assays
In vivo in the rat parathyroid, PTH mRNA stability is deterï¿¾mined by the regulated binding of AUF1 and KSRP to the
PTH mRNA 3'-UTR [20]. To identify protein-mRNA interï¿¾actions in the CaR transfected cells, we performed RNA
immunoprecipitation (RIP) assays using extracts from
HEK293 cells transfected with the CaR or control plasï¿¾mids. Immunoprecipitation was performed with antibodï¿¾ies to AUF1, KSRP or control IgG followed by qRT PCR of
the recovered RNA and input extracts. Parathyroid horï¿¾mone mRNA was decreased in the CaR expressing extracts
compared with control extracts (Figure 3A) as above (Figï¿¾ure 1D, 1E and 1G). The RIP assay showed that the
amount of PTH mRNA bound to AUF1 was decreased in
CaR-expressing cells compared with control cells (Figure
3B). In contrast, PTH mRNA bound to KSRP was increased
in the CaR-expressing cells (Figure 3C). This binding patï¿¾tern is consistent with the stabilizing function of AUF1
and the destabilizing function of KSRP on PTH mRNA
[18,20]. The increased binding to KSRP and the decreased
Over-expression of the CaR decreases PTH mRNA levels in co-transfected HEK293 cells Figure 1 (see previous page)
Over-expression of the CaR decreases PTH mRNA levels in co-transfected HEK293 cells. HEK293 cells were 
transiently co-transfected in triplicate with expression plasmids for the hPTH gene and control GFP or GH and either the CaR 
(CaR+) or empty vector (CaR-). A. Schematic representation of the human PTH expression plasmid used for transient transï¿¾fections. The boxes show the CMV promoter (grey) and the PTH exons with the untranslated regions (UTRs) (white) and codï¿¾ing regions (diagonal lines). The arrows show the pre, pro and mature PTH. B. Immunohistochemistry on whole cells using an 
intact cell enzyme-linked immunoassay for the cell surface expression of the CaR. Untransfected (background), CaR (+) or 
control plasmid (-) transfected cells were analyzed using a CaR antibody or IgG (-). C. Immunoblot analysis of extracts from 
HEK293 cells co-transfected with expression plasmids for the CaR and myc-AUF1 as control plasmid, using anti-CaR or myc 
antibodies. D-G. Effect of CaR on PTH expression. D. Northern blot for hPTH and co-transfected GFP with the CaR (+) or an 
empty vector (-). Ethidium bromide staining of the membrane is shown as a loading control. E. qPCR for PTH and co-transï¿¾fected GH mRNA levels from cells with (red) and without (blue) the CaR. F. Secreted PTH from cells as above 1 h after an 
incubation in fresh medium, 1 mM Ca2+. G. qRT-PCR for PTH mRNA levels from cells without and with either the CaR or the 
PTH1R (checkered). Data in D-G are expressed as fold change (mean Â± SE) (n = 3). *, P < 0.01, CaR: control.

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 5 of 13
(page number not for citation purposes)
The CaR decreases PTH mRNA levels and stability through the PTH mRNA 3'-UTR Figure 2 cis element
The CaR decreases PTH mRNA levels and stability through the PTH mRNA 3'-UTR cis element. A. Effect of 
CaR over-expression on reporter GH mRNA containing the PTH mRNA ARE. qRT-PCR for GH and control HPRT mRNA 
levels in cells transfected with either control (CaR-) or CaR (CaR+) and expression plasmids for GH (left panel), GH containï¿¾ing the PTH mRNA 63 nt ARE (GH-PTH63) (middle panel) or GH containing a 40 nt truncated ARE (GH-tPTH40) (right 
panel). Results are fold changes compared with cells without the CaR expressed as mean Â± SE of three experiments. *, P < 
0.05. B. Effect of CaR on PTH mRNA decay. Representative IVDA of transcripts for the full-length hPTH mRNA and the PTH 
mRNA with an internal deletion of the 3'-UTR ARE, incubated with extracts from cells expressing either the CaR or empty 
vector. C. Quantification of the amount of intact transcripts remaining with time related to time 0 (mean Â± SE, in three repeat 
experiments; *, P < 0.05). Blue square, full length PTH mRNA without CaR (CaR-) and red square, with CaR (CaR+); blue triï¿¾angle, PTH w/o ARE without CaR (CaR-) and red triangle, with the CaR, (CaR+). intact PTH mRNA (fold change)
0
0.2
0.4
0.6
0.8
1
1.2
10 30 60 90
CaR- full-length
CaR+ full-length
CaR- w/o element
CaR+ w/o element
*
*
B C
0 10 30 60 90 0 10 30 60 90
PTH
-element
PTH
CaR - +
min
A
0
0.5
1
1.5
GH GH-PTH63 GH-tPTH40 
GH/hHPRT mRNA 
(fold change)
0
2
*
GH/hHPRT mRNA 
(fold change)
GH/hHPRT mRNA 
(fold change)
CaR - CaR + CaR - CaR + CaR - CaR + 0
0.5
1
1.5
0.5
1
1.5

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 6 of 13
(page number not for citation purposes)
binding to AUF1 correlate with the lower levels of PTH
mRNA induced by the CaR in the transfected cells.
The calcium receptor leads to post-translational 
modification of the parathyroid hormone mRNA binding 
protein AUF1
In vivo dietary-induced hypocalcemia and hypophosï¿¾phatemia as well as adenine-induced renal failure and the
calcimimetic R568 lead to post-translational modificaï¿¾tions of AUF1 as shown by 2D gels [7,27]. To determine
whether the effect of the CaR on PTH mRNA stability in
the engineered cells involves post-translational modificaï¿¾tions of AUF1 as it does in the parathyroid, we performed
2D gels on extracts from HEK293 cells transfected with the
CaR expression plasmid or an empty vector as control.
AUF1 has four isoforms of p37, p40, p42 and p45. There
was no difference in AUF1 protein levels in the 1D gels
between cells with and without the CaR, apart from a
small decrease in p45 in the CaR-expressing cells (Figure
4A). However, 2D gels showed that endogenous AUF1
isoforms p37, p40 and p42 had a different distribution of
the spots between extracts of cells with and without the
CaR (Figure 4B). These results suggest that the CaR
induces post-translational modifications in AUF1 in the
transfected cells.
To analyze the four isoforms of AUF1 separately, we utiï¿¾lized myc-tagged AUF1 expression plasmids. HEK293
cells were transiently transfected with expression plasmids
for myc- p37, p40, p42 or p45 isoforms of AUF1 together
with the CaR or control plasmids. Cell extracts were anaï¿¾lyzed on 2D gels with an anti-myc antibody. CaR expresï¿¾sion led to changes in mobility of myc-AUF1 p37, p40
and also p45 but not p42 (Figure 4C). Unlike the changes
in myc-AUF1 p45, endogenous AUF1 p45 was only
slightly modified by CaR signaling. The change in endogï¿¾enous p42 was not reflected in the myc-tagged transfected
p42. The reasons for these discrepancies are not clear.
AUF1 p40 undergoes reversible phosphorylation which
may regulate ARE-directed mRNA turnover [31,32]. We
therefore added a non-specific phosphatase to extracts
from cells expressing myc-p40 with or without the CaR.
Calf intestinal phosphatase (CIP) treatment of control
extracts modified AUF1 to the form present in CaRï¿¾expressing extracts (Figure 4D). Treatment with CIP had
no further effect on the CaR-expressing extracts. These
results indicate that the CaR modifies AUF1 post-translaï¿¾tionally and suggests that at least part of this change
involves phosphorylation of isoform p40.
Expression of the CaR in HEK293 cells decreases AUF1 and increases KSRP interaction with the PTH mRNA Figure 3
Expression of the CaR in HEK293 cells decreases AUF1 and increases KSRP interaction with the PTH mRNA. 
RNA immunoprecipitation (RIP) analysis of extracts from cells transiently transfected with expression plasmids for PTH and 
GH as control and either the CaR plasmid or empty vector. Immunoprecipitation was performed using antibodies for AUF1, 
KSRP or control IgG. Input (A) and immunoprecipitiated (B, C) samples were analyzed by qPCR for PTH and GH mRNA. 
Results are presented as PTH mRNA corrected for GH mRNA. PTH mRNA in the immunoprecipitated samples was corï¿¾rected for PTH mRNA in the input. The results are mean Â± SE of three repeat experiments. *, P < 0.05 compared with cells 
transfected with empty vector (CaR-).
A B C
hPTH/GH mRNA (fold change) 
0
input
0
0.2
0.4
0.6
0.8
1
1.2
IP-AUF1
0
2
4
6
8
10
IP-KSRP
corrected hPTH/input
0.2
0.4
0.6
0.8
1
1.2
*
*
*
CaR - CaR + CaR - CaR + CaR - CaR + 

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 7 of 13
(page number not for citation purposes)
AUF1 is post-translationally modified in HEK293 cells transfected with CaR Figure 4
AUF1 is post-translationally modified in HEK293 cells transfected with CaR. A. 1D gels for AUF1 and D-tubulin as a 
loading control. B. 2D gel analysis for endogenous AUF1 in extracts from cells transiently transfected with the CaR (CaR+) 
plasmid or empty vector (CaR-). Molecular weight markers are shown on the right and the four AUF1 isoforms are indicated. 
C. 2D gel analysis of extracts from cells transiently transfected with the CaR plasmid or empty vector and the myc-AUF1 isoï¿¾forms p37, p40, p42 or p45 separately. D. 2D analysis of extracts from cells transiently transfected with the CaR plasmid or 
empty vector and myc-AUF1p40 without and after treatment with a non-specific phosphatase (CIP). The results all represent 
one of two repeat experiments with similar results.
D
   
	
myc
	
myc
	
myc
	
myc
   
	
myc
	
myc 
 
   
B 


 
 



   
C
A
Ä®
  
	






BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 8 of 13
(page number not for citation purposes)
Parathyroid hormone mRNA levels are regulated by 
[Ca2+]o and the calcimimetic R568 through the calcium 
receptor
We then studied the effect of a low-calcium medium on
the regulation of PTH gene expression by the CaR in the
transfected cells. HEK293 cells transiently co-transfected
with expression plasmids for PTH and the CaR or a conï¿¾trol plasmid were grown in a medium with either 0.2 or
1.2 mM Ca2+. Expression of the CaR decreased PTH
mRNA in cells grown in physiological 1.2 mM Ca2+ conï¿¾centration by both Northern blots and qRT PCR (Figure
5A and 5B) as in Figure 1. Importantly, the low-Ca2+
medium attenuated the decrease in PTH mRNA levels
induced by the CaR (Figure 5A and 5B). There was no
effect of a low-Ca2+ medium in cells that did not express
the CaR.
Calcimimetics are compounds that bind and activate the
CaR [5]. We then performed the same experiments with
and without the calcimimetic, R568 (Figure 4C). The CaR
decreased PTH mRNA levels as before at 1.2 mM Ca2+
(Figure 5C). Activation of the CaR by R568 decreased PTH
mRNA levels at 1.2 mM Ca2+ (Figure 5C) and also at 0.2
mM Ca2+ (Figure 5D). 0.2 mM Ca2+ prevented the
Expression of the CaR decreases PTH mRNA levels and confers responsivity to a low [Ca2+]o Figure 5 and the calcimimetic R568
Expression of the CaR decreases PTH mRNA levels and confers responsivity to a low [Ca2+]o and the calcimiï¿¾metic R568. A. Representative Northern blot analysis for PTH mRNA in cells transiently transfected in triplicate with hPTH 
and either the CaR plasmid or empty vector. After transfection cells were grown in 1.2 or 0.2 mM Ca2+ medium for an addiï¿¾tional 48 h. Ethidium bromide staining of the membrane is shown as loading control. B. qRT PCR for PTH corrected for coï¿¾transfected GH mRNAs for cells treated as in A. C. qPCR for PTH and HPRT mRNAs from cells expressing the hPTH gene 
and the CaR (CaR+) or empty vector (CaR-) in cells grown in 1.2 mM Ca2+ supplemented with either R568 or vehicle. The 
results in A-C represent one of three repeat experiments performed in triplicate with similar results. D. Representative 
Northern blot for PTH and GFP mRNA levels in cells transfected with PTH and GFP and either CaR (CaR+) or empty vector 
(CaR-). The cells were grown in 0.2 mM calcium supplemented with R568 or vehicle. Quantification of the results is shown 
below the gel. The results are presented as mean Â± SE of two repeat experiments performed in triplicate. *, P < 0.05, 
CaR+:CaR-; **, P < 0.05, CaR+, treated:CaR+, untreated.
control CaR
calcium (mM) 1.2 0.2 1.2 0.2
PTH
28S
18S
A
0
0.5
1.0
1.5
R568 - + - + 
CaR - CaR +
PTH/hHPRT mRNA
(Fold change)
*
**
C
calcium (mM) 1.2 0.2 1.2 0.2
BPTH/GH mRNA
(fold change)
0
0.5
1.0
1.5
*
CaR - CaR +
hPTH
D
CaR - +
R568 - + - + 
GFP
28S
18S
hPTH/GFP 1Â±0.01 1.12Â±0.06 1.03Â±0.03 0.85Â±0.01*,**

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 9 of 13
(page number not for citation purposes)
decrease in PTH mRNA levels due to the CaR (Figure 5B
and 5D). However, at 0.2 mM Ca2+ the addition of R568
still effectively decreased PTH mRNA levels (Figure 5D).
There was no effect of CaR expression on co-transfected
GFP mRNA levels (Figure 5D) used as a control for transï¿¾fection efficiency and loading. There was also no effect of
R568 on PTH mRNA levels in cells co-transfected with the
control plasmid that did not express the CaR (Figure 5C
and 5D). The effect of R568 on PTH mRNA levels in the
CaR-transfected cells at 0.2 mM Ca2+ indicates that the calï¿¾cimimetic is effective at activating the CaR even when the
CaR is in a relaxed configuration. Therefore, in these engiï¿¾neered cells, the CaR is permissive for the effect of [Ca2+]o
and R568 on PTH mRNA levels.
Discussion
Primary bovine parathyroid cells in culture have been sucï¿¾cessfully used for the study of PTH secretion in the short
term (hours) but not for longer term effects on PTH gene
expression. This is because these primary monolayer culï¿¾tures of parathyroid cells lose the expression of the CaR
after 24 h in culture [33]. Parathyroid organoid cultures
retain a prolonged calcium response and regulation of
PTH mRNA stability by high [Ca2+]o and a calcimimetic
[34,35]. However, there is no parathyroid cell line. Kifor
et al [25] showed that the CaR activated the phosphotyroï¿¾sine kinase in both CaR-transfected HEK293 cells and
native bovine parathyroid cells. In CaR-expressing
HEK293 cells, [Ca2+]o activates PI-PLC, PLA2 and PLD,
similar to the effect in bovine primary parathyroid cell
cultures [25,26,36]. There have been no studies on the
effect of the CaR on the regulation of PTH gene expression
using the transfected HEK293 cells. We therefore
expressed the CaR together with the hPTH gene in
HEK293 cells. The effect of [Ca2+]o and the calcimimetic
R568 on PTH expression in the parathyroid in vivo is preï¿¾dominantly post-transcriptional, regulating PTH mRNA
stability and not transcription through the PTH promoter
[7,15]. This allowed us to use a viral promoter upstream
of the hPTH gene to study the effect of the CaR signaling
on PTH mRNA levels. The PTH gene was efficiently tranï¿¾scribed, processed and translated to mature immunoreacï¿¾tive PTH. Significantly, PTH mRNA and secreted PTH
levels were decreased in cells expressing the CaR comï¿¾pared with control cells. The calcium concentration in the
medium was 1.2 mM, which would activate the CaR to
reduce PTH mRNA levels in the CaR-transfected cells.
Therefore, the CaR suppresses PTH gene expression postï¿¾transcriptionally by acting on PTH mRNA driven by a viral
and not the native PTH promoter. In vitro degradation
assays using extracts from cells with or without the CaR
showed that expression of the CaR led to a decrease in
full-length PTH mRNA half-life but not the half-life of a
PTH mRNA with an internal deletion of the PTH mRNA
ARE. The decreased PTH mRNA stability correlated with
decreased PTH mRNA steady state levels.
Dietary-induced changes in serum calcium and phosphate
levels regulate PTH gene expression in vivo post-transcripï¿¾tionally [14,15]. This regulation is mediated by the
changes in binding of stabilizing trans-acting factors,
AUF1 and Unr, and the destabilizing protein KSRP, to the
defined cis-acting ARE in the PTH mRNA 3'-UTR [16,18-
20]. The role of the PTH mRNA ARE in the regulation of
PTH mRNA levels by the CaR was demonstrated by transï¿¾fection experiments using a GH reporter mRNA containï¿¾ing the PTH mRNA 63 nt ARE. The CaR decreased GHï¿¾PTH ARE mRNA levels but had no effect on native GH
mRNA or a GH mRNA containing a truncated PTH mRNA
ARE. Calcium receptor-transfected HEK293 cells showed
increased KSRP-PTH mRNA binding and decreased AUF1-
PTH mRNA binding by RIP analysis, correlating with the
decreased PTH mRNA levels and stability in the CaRï¿¾transfected cells. Therefore, the signaling of the CaR in the
parathyroid is maintained in the transfected cells as
reflected in changes in AUF1 and KSRP PTH mRNA interï¿¾actions and the role of the PTH mRNA ARE in this regulaï¿¾tion.
AUF1-PTH mRNA binding is increased by hypocalcemia
or chronic kidney disease, or decreased by hypophosï¿¾phatemia or administration of the calcimimetic R568
[7,15]. These changes in serum Ca2+ or phosphate and
kidney disease are associated with post-translational
modifications of AUF1. AUF1 isoforms p40 and p42 are
modified by dietary-induced hypocalcemia, and the secï¿¾ondary hyperparathyroidism of chronic kidney disease
and its treatment by R568 [7,27]. We now show that
expression of the CaR in the engineered cells also induces
post-translational modifications in both endogenous
AUF1 and myc-tagged transfected AUF1 isoforms that are
similar to the modifications in vivo in the parathyroid. The
modification of at least AUF1 p40 involves phosphorylaï¿¾tion where expression of the CaR is associated with
dephosphorylation. Post-translational modifications of
this isoform, AUF1 p40, are altered concomitant with
changes in RNA binding activity and stabilization of AREï¿¾containing mRNAs in phorbol ester-treated monocytic
leukemia cells [32]. AUF1 p40 recovered from polysomes
was phosphorylated on Ser83 and Ser87 in untreated cells
but lost these modifications following phorbol ester treatï¿¾ment. It was suggested that selected signal transduction
pathways may regulate ARE-directed mRNA turnover by
reversible phosphorylation of AUF1 p40 [31,32]. Thereï¿¾fore, both in the CaR-transfected cells and in the phorbol
ester-treated cells, dephosphorylation of AUF1 p40, is
associated with decreased AUF1 activity. In the case of
PTH mRNA, inactivity of AUF1 results in a less stable PTH

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 10 of 13
(page number not for citation purposes)
mRNA after expression of the CaR, as AUF1 is a PTH
mRNA stabilizing protein [18,27].
We also show that expression of the CaR conferred
responsiveness to low [Ca2+]o and the calcimimetic R568,
underlining the relevance of this cellular model to the parï¿¾athyroid. A low- [Ca2+]o medium increased PTH expresï¿¾sion only in the cells expressing the CaR. Similarly, R568
decreased PTH expression through the CaR at both 1.2
and 0.2 mM [Ca2+]o. Therefore, regulation of PTH mRNA
levels by expression of the CaR itself and both its activaï¿¾tion by the calcimimetic and its relaxation by a low
[Ca2+]o are maintained in these transfected cells. This is
the first demonstration that the CaR can regulate PTH
gene expression in heterologous cells. This regulation is
obtained through the post-transcriptional mechanisms
that involve changes in PTH mRNA-protein interactions
in the parathyroid (Table 1). It is likely that PTH secretion
would exhibit a similar regulation by calcium as PTH
mRNA levels, given its dependence on the latter. Howï¿¾ever, secretion was not measured as a function of the
extracellular calcium concentration in the heterologous
HEK293 cell system, in which there is a prominent comï¿¾ponent of constitutive secretion, unlike the parathyroid
cell [37,38]. Secretion in HEK293 cells may be independï¿¾ently regulated by the CaR although we have not studied
this question. The parathyroid cell is unique in that the
stimulus for secretion, gene expression and cell proliferaï¿¾tion is a low [Ca2+]o and not a high [Ca2+]o. Inverse conï¿¾trol of secretion by a low [Ca2+]o of PTHrP secretion also
occurs in the epithelial cells of the lactating breast and cerï¿¾tain breast cell lines [39,40]. In addition high [Ca2+]o
decreases hormone secretion in the secretion of renin by
renal juxtaglomerular cells [41]. Calcium receptor activaï¿¾tion increases cell proliferation in cultured cells [42], but
inhibits parathyroid proliferation in vivo [43]. It is remarkï¿¾able and intriguing that despite these differences, the
transfected cell system retains so many of the native charï¿¾acteristics of the unique parathyroid cell, specifically the
relationship between calcium and PTH mRNA stability.
The CaR-mediated decrease in PTH expression in these
cells mirrors the marked increase in serum PTH in vivo in
mice and men with inactivating mutations of the CaR
[6,10,36,43,44]. These results support the concept that
the parathyroid cell is geared to constitutively synthesize
and secrete PTH, and it is the presence of a functioning
CaR that tonically inhibits PTH expression and secretion
and allows responsivity to [Ca2+]o.
Conclusion
The expression of the CaR in transfected HEK293 cells
decreases PTH gene expression post-transcriptionally and
is sufficient to confer the regulation of PTH gene expresï¿¾sion by [Ca2+]o and a calcimimetic, R568. The CaR
decreases PTH gene expression in these engineered cells
through the balanced interactions of the trans-acting facï¿¾tors KSRP and AUF1 with PTH mRNA and the PTH mRNA
ARE, as in vivo in the parathyroid. This is the first demonï¿¾stration that the CaR can regulate PTH gene expression in
heterologous transiently transfected cells.
Methods
Cells and transfection
HEK293 cells were transiently co-transfected in a 10 cm
dish with 5 Pg expression plasmids for the PTH gene and
the CaR plasmid or a control plasmid using a Calcium
Phosphate Transfection Kit (Sigma, St Louis, MO, USA).
At 48 h the cells expressing the CaR or controls were
detached and replated in 24 well plates and treated as
indicated, in triplicates for 48 h. Cells were grown in
DMEM supplemented with 10% Fetal Bovine Serum (Bioï¿¾logical Industries, Beit Haemek, Israel), L-Glutamine (Bioï¿¾Table 1: Regulation of PTH gene expression in HEK293 cells transfected with the CaR and hPTH plasmids and in the rat parathyroid 
by calcium
HEK293 cells + CaR Rat parathyroid
PTH transcription not applicable no effect
PTH mRNA levels regulated regulated
PTH mRNA stability regulated regulated
PTH secretion unknown regulated
AUF1 and KSRP-PTH mRNA interactions regulated regulated
AUF1 protein modifications regulated regulated
regulation by [Ca2+]o and R568 regulated regulated
AUF1 = AU rich binding factor; KSRP = KH domain splicing regulatory protein; PTH = parathyroid hormone

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 11 of 13
(page number not for citation purposes)
logical Industries, Beit Haemek, Israel) and Pen-Strep
solution (Biological Industries, Beit Haemek, Israel). Calï¿¾cium concentration in the medium was 1.2 mM. In some
experiments Ca2+-free DMEM medium was used (0.2 mM
Ca2+) and CaCl2 was added as indicated. R568, a gift from
Amgen (Thousand Oaks, CA, USA) was dissolved in DDW
and added to the medium at a final concentration of 1
PM.
RNA extraction and analysis
RNA extraction was performed using Tri reagent (Molecuï¿¾lar Research Center, Cincinnati, OH, USA). mRNA conï¿¾centration was determined using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies; Wilmingï¿¾ton, DE, USA). For real-time PCR 1 Pg mRNA was used as
template for RT PCR with Maxime RT PreMix (Random
primer) from iNtRON (Gyeonggi-do, Korea). qPCR was
performed using SYBR Green ROX Mix (ABgene, Surrey,
UK) according to the manufacturer's instructions in
7900HT Fast Real-Time PCR Systems from Applied Bioï¿¾systems.
The following primers were used: hPTH (5'-gggtctgcagtcï¿¾caattcat-3' and 5'-cagatttcccatccgatttt-3'), hGH (5'-gggagï¿¾gctggaagatggc-3' and 5'-cgttgtgtgagtttgtgtcgaac-3'), hHPRT
(5' tttgaatcatgtttgtgtcattagtga and 5' ttccaaactcaacttgaactctï¿¾catc). For Northern analysis RNA was run on agarose forï¿¾maldehyde gels and blotted using a Hybond-N
membrane (Amersham Biosciences, Little Chalfont, UK).
Membranes were hybridized to fragments for hPTH or
GFP [20,29]. In some experiments ethidium bromide
staining of membranes was used for quantification of 18S
or 28S as loading controls.
Plasmids
For the hPTH expression plasmid, a HpaII fragment
including the three exons and two introns of the hPTH
gene from plasmid pPTHg108 [20] was inserted downï¿¾stream of the CMV promoter in pcDNA3 expression plasï¿¾mid (Invitrogen, San Diego, CA, USA). The hCaR plasmid
was kindly provided by M Lohse (Wurzburg, Germany),
the GFP pEGFP-C1 (Clontech, Palo Alto, CA, USA) and
hGH (kindly provided by O Meyuhas, Jerusalem, Israel
[45]) were used as controls. The GH-PTH63 or GHï¿¾tPTH40 expression plasmids contained 63 bp or a trunï¿¾cated 40 bp fragments of the PTH mRNA 3'-UTR ARE that
were inserted between the coding region and the 3'-UTR
of GH mRNA [29]. hPTH1R was provided by MA Levine,
Cleveland, OH, USA). In some experiments cells co-transï¿¾fected with the GFP plasmid were analyzed by fluorescent
microscopy to estimate transfection efficiency, which was
always >90%.
Immunoreactive parathyroid hormone
Medium was replaced 1 h prior to collection and analyzed
using the Immulite 2000 Intact PTH assay (Los Angeles,
CA, USA)
In Vitro Degradation Assays
Radiolabeled transcripts (200,000 cpm) were incubated
with 40 Pg protein extract from cells in a volume of 50 Pl
and in a reaction buffer containing 3 mM Tris HCl, pH
7.5, 2 mM MgCl2, 3 mM NaCl, 10 mM ATP and 30 units
RNasin. At timed intervals samples were removed, RNA
extracted, separated on agarose gels and analyzed by autoï¿¾radiography as described [15].
The following plasmids were used as templates for RNA
transcription: pBluescript II KS plasmid containing either
the full-length rat PTH cDNA (772 bp) or a PTH cDNA
with an internal deletion of the PTH mRNA ARE and a
stretch of ~150 dT nucleotides that by in vitro transcription
produced a poly(A) tail. The plasmids were linearized
with SmaI [20].
2D gel electrophoresis
Analysis was performed as previously described [27].
RNA immunoprecipitation
Transiently transfected cells were grown in a 14 cm dish
for 48 h, collected in ice-cold PBS, pelleted and re-susï¿¾pended in RIPA buffer (containing 150 mM NaCl, 1%
NP40, 0.5% sodium deoxycholate, 0.1% SDS and proï¿¾tease inhibitors) supplemented with RNase inhibitors
(Promega, Madison, WI, USA) and homogenized by
pipetting. Equal amounts of whole cell extracts were
immunoprecipitated with Protein A agarose-bound antiï¿¾KSRP or AUF1 antibody beads (Calbiochem, Darmstadt,
Germany) or IgG as control after incubation for 2 hr at
4Â°C. The beads were then washed with modified RIPA
buffer (supplemented with 1 M NaCl, 1% Sodium Deoxï¿¾ycholate, 1 mM EDTA and 2 M urea). RNA was extracted
and analyzed by qPCR for PTH and GH mRNA using
SYBR Green ROX Mix as described above.
Intact cell enzyme-linked immunoassay
The assay was performed as previously described [27]. In
brief: 48 h after transfection cells were detached in PBS
supplemented with BSA and EDTA. The cells were then
pelleted and incubated for 1 h at 4Â°C with the anti-CaR
antibody followed by PBS wash (Ã— 3) and incubation with
the secondary HRP-conjugated antibody. Cells were then
washed (Ã— 3) prior to adding the HRP substrate and the
fluorescent signal was visualized using an electrochemiluï¿¾minescent reader.

BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 12 of 13
(page number not for citation purposes)
Antibodies
Anti-KSRP was a gift from R Gherzi, Genoa, Italy. Antiï¿¾AUF was from Upstate (Charlottesville, VA, USA). Antiï¿¾myc was from Cell Signaling (Boston, MA, USA). Anti-CaR
was from Abcam (Cambridge, UK).
Statistics
Statistical analysis was performed using Microsoft Excel
(Microsoft Corporation, Redmond, WA, USA). Values are
reported as mean Â± SEM unless stated otherwise. A 2-
tailed Student's T-test was used to assess differences from
the control group. A P value of less than 0.05 was considï¿¾ered significant.
Abbreviations
ARE: AU-rich element; AUF1: AU rich binding factor; CaR:
calcium receptor; CIP: calf intestinal phosphatase; GFP:
green fluorescent protein; HEK: human embryonic kidï¿¾ney; HPT: hyperparathyroidism; IVDA: in vitro degradaï¿¾tion assay; KSRP: KH domain splicing regulatory protein;
PTH: parathyroid hormone; qRT PCR: quantitative reverse
transcriptase polymerase chain reaction; RIP: RNA immuï¿¾noprecipitation; TM: transmembrane; UTR: untranslated
region.
Authors' contributions
Most experiments were performed by HG who also conï¿¾ceived and designed the experiments. VL-M performed the
experiments in Fig 4Câ€“D and MN and TM assisted in difï¿¾ferent experiments. JS and TN-M conceived, designed and
wrote the manuscript. All authors read and approved the
final manuscript.
Acknowledgements
This work was supported in part by the American Society of Bone and Minï¿¾eral Research Bridging Fund and grants from the Israel Academy of Sciences 
and Amgen.
References
1. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O,
Sun A, Hediger MA, Lytton J, Hebert J: Cloning and characterizaï¿¾tion of an extracellular Ca2+-sensing receptor from bovine
parathyroid. Nature 1993, 366:575-580.
2. Silver J, Naveh-Many T, Kronenberg HM: Parathyroid hormone:
molecular biology. In Principles of bone biology Edited by: Bilezikian
JB, Raisz LG, Rodan GA. San Diego: Academic Press; 2002:407-422. 
3. Rodriguez M, Nemeth E, Martin D: The calcium-sensing recepï¿¾tor: a key factor in the pathogenesis of secondary hyperparï¿¾athyroidism. Am J Physiol Renal Physiol 2005, 288:F253-F264.
4. Hofer AM, Brown EM: Extracellular calcium sensing and signalï¿¾ling. Nat Rev Mol Cell Biol 2003, 4:530-538.
5. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen
BC, DelMar EG, Balandrin MF: Calcimimetics with potent and
selective activity on the parathyroid calcium receptor. Proc
Natl Acad Sci USA 1998, 95:4040-4045.
6. Hu J, Spiegel AM: Naturally occurring mutations of the extraï¿¾cellular Ca2+-sensing receptor: implications for its structure
and function. Trends Endocrinol Metab 2003, 14:282-288.
7. Levi R, Ben Dov IZ, Lavi-Moshayoff V, Dinur M, Martin D, Navehï¿¾Many T, Silver J: Increased parathyroid hormone gene expresï¿¾sion in secondary hyperparathyroidism of experimental ureï¿¾mia is reversed by calcimimetics: correlation with
posttranslational modification of the trans acting factor
AUF1. J Am Soc Nephrol 2006, 17:107-112.
8. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey
D, Martin D: Cinacalcet HCl attenuates parathyroid hyperplaï¿¾sia in a rat model of secondary hyperparathyroidism. Kidney
Int 2005, 67:467-476.
9. Wettschureck N, Lee E, Libutti SK, Offermanns S, Robey PG, Spiegel
AM: Parathyroid-specific double knockout of Gq and G11
alpha-subunits leads to a phenotype resembling germline
knockout of the extracellular Ca2+ -sensing receptor. Mol
Endocrinol 2007, 21:274-280.
10. Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown
EM, Seidman JG, Seidman CE: A mouse model of human familial
hypocalciuric hypercalcemia and neonatal severe hyperparï¿¾athyroidism. Nat Genet 1995, 11:389-394.
11. Kos CH, Karaplis AC, Peng JB, Hediger MA, Goltzman D, Mohammad
KS, Guise TA, Pollak MR: The calcium-sensing receptor is
required for normal calcium homeostasis independent of
parathyroid hormone. J Clin Invest 2003, 111:1021-1028.
12. Tu Q, Pi M, Karsenty G, Simpson L, Liu S, Quarles LD: Rescue of the
skeletal phenotype in CasR-deficient mice by transfer onto
the Gcm2 null background. J Clin Invest 2003, 111:1029-1037.
13. Silver J, Kilav R, Naveh-Many T: Mechanisms of secondary hyperï¿¾parathyroidism. Am J Physiol Renal Physiol 2002, 283:F367-F376.
14. Kilav R, Silver J, Naveh-Many T: Parathyroid hormone gene
expression in hypophosphatemic rats. J Clin Invest 1995,
96:327-333.
15. Moallem E, Silver J, Kilav R, Naveh-Many T: RNA protein binding
and post-transcriptional regulation of PTH gene expression
by calcium and phosphate. J Biol Chem 1998, 273:5253-5259.
16. Kilav R, Silver J, Naveh-Many T: A conserved cis-acting element
in the parathyroid hormone 3'-untranslated region is suffiï¿¾cient for regulation of RNA stability by calcium and phosï¿¾phate. J Biol Chem 2001, 276:8727-8733.
17. Bell O, Silver J, Naveh-Many T: Identification and characterizaï¿¾tion of cis -acting elements in the human and bovine parathï¿¾yroid hormone mRNA 3'-untranslated region. J Bone Miner Res
2005, 20:858-866.
18. Sela-Brown A, Silver J, Brewer G, Naveh-Many T: Identification of
AUF1 as a parathyroid hormone mRNA 3'-untranslated
region binding protein that determines parathyroid horï¿¾mone mRNA stability. J Biol Chem 2000, 275:7424-7429.
19. Dinur M, Kilav R, Sela-Brown A, Jacquemin-Sablon H, Naveh-Many T:
In vitro evidence that upstream of N-ras participates in the
regulation of parathyroid hormone messenger ribonucleic
acid stability. Mol Endocrinol 2006, 20:1652-1660.
20. Nechama M, Ben Dov IZ, Briata P, Gherzi R, Naveh-Many T: The
mRNA decay promoting factor K-homology splicing regulaï¿¾tor protein post-transcriptionally determines parathyroid
hormone mRNA levels. FASEB J 2008, 22:3458-3468.
21. Brown EM, Gardner DG, Aurbach GD: Effects of the calcium
ionophore A23187 on dispersed bovine parathyroid cells.
Endocrinology 1980, 106:133-138.
22. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro
S, Torres A, Rodriguez M: Direct effect of phosphorus on parï¿¾athyroid hormone secretion from whole rat parathyroid
glands in vitro. J Bone Miner Res 1996, 11:970-976.
23. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabï¿¾olites of messenger ribonucleic acid for preproparathyroid
hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci
USA 1985, 82:4270-4273.
24. Moallem E, Silver J, Naveh-Many T: Regulation of parathyroid
hormone messenger RNA levels by protein kinase A and C
in bovine parathyroid cells. J Bone Miner Res 1995, 10:447-452.
25. Kifor O, Diaz R, Butters R, Brown EM: The Ca2+-sensing recepï¿¾tor (CaR) activates phospholipases C, A2, and D in bovine
parathyroid and CaR-transfected, human embryonic kidney
(HEK293) cells. J Bone Miner Res 1997, 12:715-725.
26. Kifor O, MacLeod RJ, Diaz R, Bai M, Yamaguchi T, Yao T, Kifor I,
Brown EM: Regulation of MAP kinase by calcium-sensing
receptor in bovine parathyroid and CaR-transfected
HEK293 cells. Am J Physiol Renal Physiol 2001, 280:F291-F302.
27. Bell O, Gaberman E, Kilav R, Levi R, Cox KB, Molkentin JD, Silver J,
Naveh-Many T: The protein phosphatase calcineurin deterï¿¾mines basal parathyroid hormone gene expression. Mol Endoï¿¾crinol 2005, 19:516-526.

Publish with BioMed Central and every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours â€” you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biology 2009, 7:17 http://www.biomedcentral.com/1741-7007/7/17
Page 13 of 13
(page number not for citation purposes)
28. Ray K, Fan GF, Goldsmith PK, Spiegel AM: The carboxyl terminus
of the human calcium receptor. Requirements for cell-surï¿¾face expression and signal transduction. J Biol Chem 1997,
272:31355-31361.
29. Kilav R, Bell O, Le SY, Silver J, Naveh-Many T: The parathyroid
hormone mRNA 3'-untranslated region AU-rich element is
an unstructured functional element. J Biol Chem 2004,
279:2109-2116.
30. Fritz DT, Ford LP, Wilusz J: An in vitro assay to study regulated
mRNA stability. Sci STKE 2000, 2000:L1.
31. Wilson GM, Lu J, Sutphen K, Sun Y, Huynh Y, Brewer G: Regulation
of A + U-rich element-directed mRNA turnover involving
reversible phosphorylation of AUF1. J Biol Chem 2003,
278:33029-33038.
32. Wilson GM, Lu J, Sutphen K, Suarez Y, Sinha S, Brewer B, Villanuevaï¿¾Feliciano EC, Ysla RM, Charles S, Brewer G: Phosphorylation of
p40AUF1 regulates binding to A + U-rich mRNA-destabilizï¿¾ing elements and protein-induced changes in ribonucleoproï¿¾tein structure. J Biol Chem 2003, 278:33039-33048.
33. Brown AJ, Zhong M, Ritter C, Brown EM, Slatopolsky E: Loss of calï¿¾cium responsiveness in cultured bovine parathyroid cells is
associated with decreased calcium receptor expression. Bioï¿¾chem Biophys Res Commun 1995, 212:861-867.
34. Ritter CS, Slatopolsky E, Santoro S, Brown AJ: Parathyroid cells
cultured in collagen matrix retain calcium responsiveness:
importance of three-dimensional tissue architecture. J Bone
Miner Res 2004, 19:491-498.
35. Ritter CS, Pande S, Krits I, Slatopolsky E, Brown AJ: Destabilization
of parathyroid hormone mRNA by extracellular Ca2+ and
the calcimimetic R-568 in parathyroid cells: role of cytosolic
Ca and requirement for gene transcription. J Mol Endocrinol
2008, 40:13-21.
36. Pearce SH, Bai M, Quinn SJ, Kifor O, Brown EM, Thakker RV: Funcï¿¾tional characterization of calcium-sensing receptor mutaï¿¾tions expressed in human embryonic kidney cells. J Clin Invest
1996, 98:1860-1866.
37. Groskreutz DJ, Sliwkowski MX, Gorman CM: Genetically engiï¿¾neered proinsulin constitutively processed and secreted as
mature, active insulin. J Biol Chem 1994, 269:6241-6245.
38. Beuret N, Stettler H, Renold A, Rutishauser J, Spiess M: Expression
of regulated secretory proteins is sufficient to generate granï¿¾ule-like structures in constitutively secreting cells. J Biol Chem
2004, 279:20242-20249.
39. Mamillapalli R, VanHouten J, Zawalich W, Wysolmerski J: Switching
of G-protein usage by the calcium-sensing receptor reverses
its effect on parathyroid hormone-related protein secretion
in normal versus malignant breast cells. J Biol Chem 2008,
283:24435-24447.
40. VanHouten J, Dann P, McGeoch G, Brown EM, Krapcho K, Neville M,
Wysolmerski JJ: The calcium-sensing receptor regulates mamï¿¾mary gland parathyroid hormone-related protein producï¿¾tion and calcium transport. J Clin Invest 2004, 113:598-608.
41. Ortiz-Capisano MC, Ortiz PA, Garvin JL, Harding P, Beierwaltes WH:
Expression and function of the calcium-sensing receptor in
juxtaglomerular cells. Hypertension 2007, 50:737-743.
42. McNeil SE, Hobson SA, Nipper V, Rodland KD: Functional calï¿¾cium-sensing receptors in rat fibroblasts are required for
activation of SRC kinase and mitogen-activated protein
kinase in response to extracellular calcium. J Biol Chem 1998,
273:1114-1120.
43. Pollack MR, Brown EM, Chou Y-HW, Hebert SC, Marx SJ, Steinman
B, Levi T, Seidman CE, Seidman JG: Mutations in the human Ca2+
-sensing receptor gene cause familial hypocalciuric hypercalï¿¾cemia and neonatal severe hyperparathyroidism. Cell 1993,
75:1297-1303.
44. Pearce SH, Williamson C, Kifor O, Bai M, Coulthard MG, Davies M,
Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown
EM, Thakker RV: A familial syndrome of hypocalcemia with
hypercalciuria due to mutations in the calcium-sensing
receptor [see comments]. N Engl J Med 1996, 335:1115-1122.
45. Levy S, Avni D, Hariharan N, Perry RP, Meyuhas O: Oligopyrimiï¿¾dine tract at the 5' end of mammalian ribosomal protein
mRNAs is required for their translational control. Proc Natl
Acad Sci USA 1991, 88:3319-3323.

